ClinicalTrials.gg
Active, not recruitingNCT06038474SLE-001Updated Mar 27, 2026

Descartes-08 for Patients With Systemic Lupus Erythematosus

A Phase 2 interventional study of Descartes-08 in Systemic Lupus Erythematosus (SLE), sponsored by Cartesian Therapeutics. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Cartesian Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Enrollment
371st of 407
6 · median 70
Started
2024
with 32 others
Phase 2
120 of 477
10 open now
Primary completion
2026-12
later than 21 of 125 live
Registered
384th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 371st largest by enrollment of the 407 interventional ones that give a count, is one of 33 that started in 2024, is one of 120 in phase 2, reaches primary completion later than 21 of the 125 other live ones, and was the 384th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)

Keywords

  • Descartes-08
  • CART
  • CAR-T
  • Autoimmune
  • Auto-antibody
  • Auto antibody
  • chimeric antigen receptor
  • T cells
  • Lupus
  • SLE
  • Lupus Erythematosus
  • Systemic Lupus Erythematosus
  • LE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be at least 18 years of age.
  • Patient must have systemic lupus erythematosus (SLE) at the time of screening.
  • Active symptoms despite recent or ongoing therapy with and at least 2 other immunosuppressive medications being tried for at least 12 weeks within 24 months of screening.
  • At least one of: anti-dsDNA, anti-histone, anti-chromatin, and/or anti-Sm antibodies detectable at screening as assessed by a CLIA-certified laboratory.

Exclusion criteria

Exclusion Criteria:

  • Active severe lupus nephritis, active severe CNS lupus, and/or neurological symptoms of SLE including headache, seizure, psychosis, and organic brain syndrome (a patient with an incidental headache, deemed unrelated to SLE, may re-screen by telephone upon resolution of the headache);
  • Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.
  • Patient is pregnant or lactating.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Other
    Descartes-08

    Drug: Descartes-08 Autologous T-cells expressing a chimeric antigen receptor directed to BCMA

    Drug: Descartes-08

Interventions

  • Autologous T-cells expressing a chimeric antigen receptor directed to BCMA

06

What researchers measure

Primary outcomes

  1. Assess safety and tolerability of Descartes-08 in patients with systemic lupus erythematosus (SLE)

    Results will be descriptive. Safety and tolerability endpoints will include descriptive statistics of AEs and SAEs. Patients must be followed until all AEs have resolved to Grade 2 or less except for lymphopenia and alopecia.

    Time frame: Day -59 to Day 50

Secondary outcomes

  1. Quantify the clinical activity of Descartes-08 in patients with SLE using Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)

    Assessment of Systemic Lupus Erythematosus Disease Activity Index 2000 from baseline administration at various timepoints up to month 12 follow up visit. A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity.

    Time frame: Day -59 to Month 12

  2. Assess the clinical activity of Descartes-08 in patients with SLE using Systemic Lupus Erythematosus Responder Index (SRI)

    Assessment of whether participants meet the Systemic Lupus Erythematosus Responder Index (SRI) criteria (Yes/No) at various timepoints up to month 12 follow up visit.

    Time frame: Day -59 to Month 12

  3. Assess the clinical activity of Descartes-08 in patients with SLE using British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA)

    Assessment of whether participants meet the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) criteria (Yes/No) at various timepoints up to month 12 follow up visit.

    Time frame: Day -59 to Month 12

  4. Quantify the clinical activity of Descartes-08 in patients with SLE using Physician Global Assessment (PGA)

    Assessment of Physician Global Assessment (PGA) from baseline administration at various timepoints up to month 12 follow up visit. A total score can fall between 0.0 and 3.0, with a higher score representing a more significant degree of disease activity.

    Time frame: Day -59 to Month 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 47. This study's planned 33 months is close to that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2023
First posted
Sep 14, 2023
StartActual
Feb 12, 2024
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06038474
Lead sponsor
Cartesian Therapeutics
Responsible party
Sponsor
First posted
Sep 14, 2023
Start date
Feb 12, 2024
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Mar 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes

Start the discussion